RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, ...

Developers of mRNA therapeutics face an increasingly complex landscape: rising expectations for potency and durability, ...

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

Ottawa, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The global mRNA synthesis & manufacturing market size is calculated at USD 1.55 billion in 2024, grows to USD 1.58 billion in 2025, and is projected to hit ...

RNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the ...

A new approach has been proposed to suppress the side effects of messenger ribonucleic acid (mRNA), opening up possibilities ...

BIOVECTRA and Revolution Biomanufacturing partner to integrate mRNA sequence design with end-to-end GMP manufacturing for ...

In two experiments, researchers have found that introducing people to "mental models" about how mRNA vaccination works and ...